Listen on the go
CORRECT!
Next question
touchHAEMATOLOGY touchHAEMATOLOGY

Start Learning

Touch Loading image
CONFERENCE HUB
Start Learning
DREPAGREFFE: Comparing stem cell transplantation and standard-of-care in paediatric sickle cell anaemia
JOURNALS
Start Learning
EHA Perspectives in Hematology: EHA2025 Congress Reports now available
Jon Edelson Clinical Expertise into Business success
JOURNALS
Start Learning
Turning your Clinical Expertise into Business Success
touchPANEL DISCUSSION
Start Learning
Tailoring treatment in myelofibrosis: Addressing anaemia and thrombocytopenia
CE/CME ACCREDITED
touchCONGRESS
Start Learning
Targeting BCMA in multiple myeloma: Insights from COMy and EHA 2024
CE/CME ACCREDITED
CONFERENCE HUB
Start Learning
#EHA2025 late-breaker: REDIRECTT-1: teclistamab + talquetamab show durable responses in EMD in multiple myeloma
JOURNALS
Start Learning
Breaking barriers beyond cancer: Dr David Porter on the expanding role of cellular therapies
JOURNALS
Start Learning
#ASH24: Discover the 2024 late-breaking abstracts
touchCONGRESS
Start Learning
Insights from EHA and ISTH 2024: How can we optimize care for patients with chronic ITP?
CE/CME ACCREDITED
touchFOCUS
Start Learning
Looking to the future in the treatment of steroid-refractory chronic GvHD
CE/CME ACCREDITED

to view Favourites, Keep Notes and Track CME Credits

Favourites
Key highlights from ASH 2024: Promising new therapies for relapsed/refractory acute myeloid leukaemia
View
Q&A with Dr Marlies Vanden Bempt: touchHAEMATOLOGY Future Leader 2025
View
Looking to the future in the treatment of steroid-refractory chronic GvHD
View
Should we intensify chemotherapy in the treatment of acute myeloid leukemia? Insights from ASH 2024
View
Bridging the gap in paediatric sickle cell care: Expanding transplant access globally
View
Turning your Clinical Expertise into Business Success
View
Empowering young haematologists: Insights from the EBMT Trainee Committee co-chairs
View
#ASCO25: Dr Miguel-Angel Perales unveils the CAR T Vision Coalition
View
Navtemadlin in myelofibrosis: Advancing treatment with MDM2 inhibition
View
Is there an alternative to intensive chemotherapy for patients with acute myeloid leukemia? Key insights from ASH 2024
View
Copied to clipboard!
accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72
Close Popup